JW Therapeutics
Shanghai based therapeutics platform.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | $300m | IPO | |
| Total Funding | 000k | ||
| CNY | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 373 % | 19 % | (9 %) | 102 % | 73 % | 49 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (2274 %) | (516 %) | (272 %) | (410 %) | (160 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (2281 %) | (581 %) | (442 %) | (373 %) | (191 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 1346 % | 280 % | 238 % | 179 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
JW Therapeutics (HKEx: 2126) operates as a clinical-stage biopharmaceutical company focused on cell-based immunotherapies for cancer patients in China. The company was established in February 2016 as a joint venture between WuXi AppTec and Juno Therapeutics (a Bristol Myers Squibb company) in Shanghai. This strategic partnership was designed to combine Juno's proficiency in Chimeric Antigen Receptor T-cell (CAR-T) technology with WuXi AppTec's local R&D, manufacturing capabilities, and market expertise in China.
The company's business model centers on the development, manufacturing, and commercialization of cell immunotherapy products. Its target clients are patients with hematological cancers and solid tumors, primarily within the Chinese market. Revenue is generated from the sale of its approved therapies. The company went public in 2020 via an IPO on the Hong Kong Stock Exchange. Co-founder Dr. James Li, who previously served as the founding general manager for Amgen in China and was a partner at Kleiner Perkins, led the company as CEO until July 2024. In July 2024, Min Liu, formerly the chief commercial officer at Innovent Biologics, was appointed CEO.
JW Therapeutics' lead product is Carteyva® (relmacabtagene autoleucel or relma-cel), an autologous anti-CD19 CAR-T therapy. This therapy involves genetically modifying a patient's own T-cells to recognize and attack cancer cells expressing the CD19 protein. In September 2021, Carteyva® received approval from China's National Medical Products Administration (NMPA) for treating adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This marked it as the first CAR-T product approved as a Category 1 biologics product in China. The company's product pipeline also includes JWCAR129, a CAR-T therapy targeting BCMA for the treatment of multiple myeloma, and it is expanding its research to cover solid tumors and autoimmune diseases through collaborations. To support its commercialization efforts, the company has established a 10,000-square-meter GMP manufacturing facility in Suzhou.
Keywords: CAR-T cell therapy, immunotherapy, oncology, biopharmaceutical, China, hematologic malignancies, large B-cell lymphoma, relma-cel, Carteyva, WuXi AppTec, Juno Therapeutics, cell therapy manufacturing, clinical-stage, multiple myeloma, solid tumors, autoimmune diseases, JWCAR029, JWCAR129, NMPA approval, biotechnology, cancer treatment